Biomarker Development
Our generalized immune decoding algorithm sets a new standard in computational immunology, reliably detecting cancer, autoimmune, neurodegenerative, and infectious diseases.
Industry-Leading Accuracy
MyImmune accurately separates a population of >1,400 donors across 15 distinct diseases with an unparalleled mean ROC AUC of 0.99.
Superior Algorithmic Efficiency
MyImmune outperforms Stanford’s Mal-ID - the only other platform to report diagnostic-grade performance on the adaptive immune repertoire to date—delivering 10% higher accuracy while relying on 50% less training data.
Accelerated Time-to-Market
Our unified protocol for biomarker discovery, identification, and development of a high-performance biomarker requires an initial training cohort of just 100-200 patients, effectively reducing your to-market costs by ~55%.
Limitless Multiplexing
Once our AI is trained on a disease’s unique "immune signature," that same disease can be diagnosed from a single blood sample with zero additional analytical cost. This enables the reliable, simultaneous testing of hundreds of hard-to-detect diseases from one standard blood draw.
Versatile Clinical & RUO Applications
Highly adaptable to a broad spectrum of research and clinical environments, our platform enables:
Early Disease Detection & Population Screening
Leverage a single, non-invasive blood draw to simultaneously screen for multiple diseases, including cancer, autoimmune, and infectious conditions, before clinical symptoms appear.
Therapy Response Prediction & Longitudinal Monitoring
Accurately stratify patients into responders and non-responders before treatment begins, achieving ROC AUCs of 0.89–0.98 across various modalities like ICIs and mAbs. Furthermore, the platform utilizes standard blood draws for frequent, non-invasive monitoring of the immune system to detect acquired resistance or recurrence early without the need for surgical biopsies.
Adverse Event Prediction & Transplant Monitoring
Proactively identify baseline immune signatures predictive of severe toxicities, such as Cytokine Release Syndrome (CRS) in cell and bispecific therapies. This capability enables clinicians to implement safer therapeutic protocols and personalized mitigation strategies before life-threatening side effects occur.
Precise Immunization Status Profiling
Provide a dynamic, functional readout of the adaptive immune system to monitor vaccine efficacy and the durability of the immune response over time. By analyzing patient data to identify the most effective antibodies naturally generated against a pathogen, this approach allows for precise profiling of population immunity and the validation of novel prophylactic and therapeutic vaccines.
Versatile Research Use Only (RUO) Applications
Deploy our highly scalable immune decoding engine for a wide range of RUO applications, including target discovery, elucidating Mechanisms of Action (MoA), and clinical trial optimization. Partners can pilot our technology for RUO use or retrospective analysis, systematically de-risking pipelines and strengthening data packages before committing to regulated diagnostic pathways.
Zero CapEx & Unparalleled Scalability
We eliminate the high infrastructure barriers of traditional diagnostic commercialization. MyImmune leverages a robust, highly commoditized NGS protocol that runs seamlessly in any sequencing-capable lab, ensuring global decentralization with zero CapEx.
Build the Future of Diagnostics With Us
We invite interested scientists and representatives of diagnostic or biomarker companies to collaborate with us. Leverage our AI to co-develop next-generation diagnostic applications and products.